8-K: Organon & Co. Reports 4% Revenue Growth in Q3 2024, Raises Full-Year Guidance Midpoint

Organon & Co. announced a 4% increase in third-quarter revenue, reaching $1.582 billion, and raised the midpoint of its full-year revenue guidance by $50 million.

Summary

• Organon & Co. reported a 4% increase in revenue for the third quarter of 2024, reaching $1.582 billion, or 5% growth at constant currency.
• The company's diluted earnings per share (EPS) was $1.38, while non-GAAP adjusted diluted EPS was $0.87, which includes a $0.16 per share impact from acquired in-process research and development (IPR&D) and milestones.
• Net income for the quarter was $359 million, and adjusted EBITDA was $459 million.
• Organon narrowed its full-year 2024 revenue guidance to $6.375 billion to $6.425 billion, raising the midpoint by $50 million.
• The company also revised its full-year adjusted EBITDA margin guidance to 30.0% to 31.0%, which includes the $51 million IPR&D expense from the third quarter.
• Women's Health revenue increased by 5% as reported and 6% ex-FX, driven by an 11% ex-FX growth in Nexplanon.
• Biosimilars revenue grew by 16% as reported and 17% ex-FX, primarily due to the uptake of Hadlima.
• Established Brands revenue grew by 2% as reported and 3% ex-FX, with growth driven by Emgality and recovery in injectable steroids.
• The company declared a quarterly dividend of $0.28 per share, payable on December 12, 2024.
• As of September 30, 2024, Organon had $763 million in cash and cash equivalents and $8.7 billion in debt.

Sentiment

Score: 7

Explanation: The sentiment is positive due to revenue growth, increased guidance, and strong performance in key product areas, but tempered by the impact of IPR&D expenses and some product declines.

Positives

• Revenue increased by 4% as reported and 5% at constant currency in the third quarter of 2024.
• The company's largest product, Nexplanon, is well positioned to deliver $1 billion of revenue next year.
• The company has been disciplined on operating costs and driving Adjusted EBITDA growth.
• The company is on track to achieve $1 billion of free cash flow before one-time costs for full year 2024.
• Biosimilars revenue grew by 16% as reported and 17% ex-FX, primarily due to the uptake of Hadlima.
• The company raised the midpoint of its full-year revenue guidance by $50 million.
• The company declared a quarterly dividend of $0.28 per share.

Negatives

• The company incurred $51 million of expense for acquired in-process research and development (IPR&D) and milestones, impacting earnings per share by $0.16.
• NuvaRing sales declined 45% ex-FX due to generic competition and increased government discount rates.
• Ontruzant sales declined 49% ex-FX due to the timing of tenders in Brazil and lower demand in the U.S. and Europe.
• The adjusted gross margin decreased due to unfavorable product mix and price.
• The adjusted EBITDA margin decreased due to the $51 million IPR&D expense.
• The company expects revenue growth in the Established Brands franchise to be approximately flat for full year 2024 on an ex-FX basis.

Risks

• Pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform.
• Inability to fully execute on product development and commercialization plans in the United States, Europe, and elsewhere internationally.
• Difficulties implementing or executing on Organon's acquisition strategy, including integrating acquisitions.
• Changes in tax laws or other tax guidance which could adversely affect cash tax liability, effective tax rates, and results of operations.
• Expanded brand and class competition in the markets in which the company operates.
• Global tensions, which may result in disruptions in the broader global economic environment.
• Governmental initiatives that adversely impact marketing activities, particularly in China.
• Political and social pressures, or regulatory developments, that adversely impact demand for, availability of, or patient access to contraception or fertility products.
• Competition from generic products as products lose patent protection.
• Failure to obtain an additional period of market exclusivity in the United States for Nexplanon.
• The impact of the 2024 United States presidential election and any resulting public policy changes affecting women and their health care decisions.
• The impact of higher selling and promotional costs.
• The impact of cyberattacks or other events that may affect Organon's information technology systems or those of third parties.

Future Outlook

The company narrowed its full-year 2024 revenue guidance to $6.375 billion to $6.425 billion and revised its full-year adjusted EBITDA margin guidance to 30.0% to 31.0%. The company expects revenue growth in the Established Brands franchise to be approximately flat for full year 2024 on an ex-FX basis. Nexplanon is expected to deliver $1 billion in revenue next year.

Management Comments

• In 2024 our commercial execution has been very strong.
• Our largest product, Nexplanon, is well positioned to deliver $1 billion of revenue next year and we've added other notable growth drivers with Emgality and most recently, VTAMA.
• Further, we have been extremely disciplined on operating costs and driving Adjusted EBITDA growth in support of achieving $1 billion of free cash flow before one-time costs for full year 2024.

Industry Context

Organon's performance reflects a mixed landscape in the pharmaceutical industry, with strong growth in some areas like biosimilars and women's health products, offset by challenges such as generic competition and pricing pressures. The company's focus on cost containment and strategic acquisitions is in line with industry trends to drive growth and profitability.

Comparison to Industry Standards

• Organon's 4% revenue growth is comparable to other established pharmaceutical companies, but the growth is driven by specific products like Nexplanon and Hadlima.
• The company's adjusted EBITDA margin of 29.0% in Q3 2024 is within the range of other pharmaceutical companies, but the $51 million IPR&D expense impacted the margin.
• The company's focus on women's health and biosimilars aligns with the industry's trend towards specialized and cost-effective treatments.
• Compared to companies like Teva and Viatris, Organon's growth is more focused on specific product lines rather than broad generic portfolios.
• The company's free cash flow target of $1 billion before one-time costs is a positive indicator of financial health, similar to other large pharmaceutical companies.

Stakeholder Impact

• Shareholders will benefit from the increased revenue guidance and the declared dividend.
• Employees may be impacted by restructuring initiatives and cost containment efforts.
• Customers will benefit from the continued availability of Organon's products.
• Suppliers may be impacted by changes in manufacturing and supply agreements.
• Creditors will be interested in the company's debt levels and cash flow.

Next Steps

• The company will continue to focus on commercial execution and cost containment.
• Organon will host a conference call to discuss the third quarter 2024 financial results.
• The company will continue to invest in innovative solutions and research to drive future growth opportunities in women's health and biosimilars.

Key Dates

Keywords

Organon, Revenue, Earnings, EBITDA, Nexplanon, Biosimilars, Womens Health, Hadlima, Emgality, Pharmaceuticals, Financial Results